Methods and Results The frequency-dependent electrophysiologic effects of sematilide (n= 11) and amiodarone (n=22) were determined at (1) drug-free baseline, (2) during steadystate (>48 hours) dosing with sematilide (455+±5 mg/d
[mean±SEM]) or after 10.5 days of amiodarone loading (1618±32 mg/d), and (3) during isoproterenol administration (35 ng/kg per minute) to patients receiving sematilide or amiodarone. Electrophysiologic determinations were made at paced cycle lengths of 300 to 500 ms. The two groups were similar in all clinical characteristics. The ventricular action potential duration at 90% repolarization (APD90) was significantly prolonged by sematilide (mean increase, 7±1%, P<.01 by ANOVA) and amiodarone (mean increase, 12±1%, P<.001). However, while sematilide-induced APD90 prolongation was fully reversed to baseline values during isoproterenol infusion, the APD90 in patients receiving amiodarone remained significantly prolonged by a mean of 6±1% compared with baseline (P=.005). The reduction in the APD,O was frequency dependent for both agents, with a greater reduction at longer than shorter paced cycle lengths (P<.02). During isoproterenol infusion the right ventricular effective refractory period (RVERP) in patients receiving sematilide was significantly reduced to mean values of 8±2% below baseline (P<.05), T Nhe negative results of the Cardiac Arrhythmia Suppression Trial using class I antiarrhythmic agents",2 and the high efficacy of amiodarone in patients with sustained ventricular arrhythmias34 have ms) to 32±5o% (paced cycle length, 300 ms) compared with baseline values. Isoproterenol attenuated amiodarone-induced QRS prolongation by a mean of 5±1% (P=.005), without frequency-dependent effects, consistent with isoproterenol-induced increases in the sodium current. During isoproterenol infusion there was a trend for the sustained VT cycle length to be reduced below baseline in patients receiving sematilide (275±16 versus 298±55 ms, P=.06), whereas it remained significantly prolonged compared with baseline in patients receiving amiodarone (327±17 versus 257+12 ms, P<.001).
Conclusions Isoproterenol fully reversed the effects of selective potassium channel block with sematilide on the APD9o and further reduced the RVERP to values significantly below baseline; it partially attenuated but did not fully reverse amiodarone-induced prolongation of the APD90 and RVERP, which remained significantly prolonged beyond baseline values. Isoproterenol exerted frequency-dependent effects in both patient groups on the APD90; it modestly attenuated amiodarone-induced conduction slowing without frequencydependent actions; and the sustained VT cycle length remained significantly prolonged during isoproterenol administration to patients receiving amiodarone but not in those receiving sematilide. These The RV effective refractory period (RVERP) was measured at the same site from which the MAP recordings were obtained. An extrastimulus was applied during late diastole after a 14-beat drive run and a 1-second pause between drive runs.
The coupling interval of the extrastimulus was successively decremented by 5 ms, and the effective refractory period was reached when the extrastimulus failed to provoke an extrasystole on two successive attempts.
The QRS duration was used as a measure of ventricular conduction and was determined during steady-state ventricular pacing by measuring from the beginning to the end of the QRS complex in ECG lead II. One blinded observer measured two QRS complexes at each paced cycle length. The intraobserver variability was <5%.
After the above determinations were made in patients receiving sematilide or amiodarone, attempts were made to induce sustained monomorphic VT using programmed ventricular stimulation at the RV apex and RV outflow tract using <3 premature extrastimuli as previously described. 
Effect on Repolarization
After sematilide administration (Fig 1) , the APD90 was significantly increased by 10±4 ms (5%), 14±5 ms (6%), 14±5 ms (6%), and 24±7 ms (10%) above baseline values at paced cycle lengths of 300, 350, 400, and 500 ms, respectively (P=.01 by ANOVA). There was a trend (P=.07 by ANOVA) over the paced cycle lengths examined for sematilide to prolong the APD90 to a greater extent at longer than at shorter paced cycle lengths (ie, "reverse" frequency-dependence). During isoproterenol infusion, the sematilide-induced prolongation of the APD90 was reduced by 13±4 ms (6%), 19±4 ms (8%), 24±4 ms (10%), and 34±9 ms (12%) at paced cycle lengths of 300, 350, 400, and 500 ms (P<.001). Thus, sematilide-induced increases in the APD90 were fully reversed, and there was a nonsignificant trend for the values to be reduced by 1±2% to 5±2% below baseline values (P=NS). Isoproterenol exerted significant frequency-dependent actions on the APD90 in patients receiving sematilide. The reduction in the APD9o during isoproterenol infusion was more 30 (Fig 3) and after isoproterenol did not effect ventricular conduction as determined by the QRS duration. Amiodarone (Fig 3) prolonged from baseline values; (3) isoproterenol exerted frequency-dependent effects in both patient groups on the APD90, with a greater reduction in the APD90 at longer than at shorter paced cycle lengths; (4) isoproterenol modestly attenuated amiodarone-induced conduction slowing without frequency-dependent effects; and (5) the sustained VT cycle length remained significantly prolonged during isoproterenol administration to patients receiving amiodarone but not in patients receiving sematilide. Effects on Conduction Sematilide, as previously described,5 had no effect on ventricular conduction, and isoproterenol did not modify the QRS duration. Amiodarone's frequency-dependent slowing of ventricular conduction is consistent with the drug's known ability to decrease Vmax by blocking Na channels and slowing their recovery during the interpulse interval.3637 The observed partial reversal of amiodarone's effects on conduction are consistent with the finding that isoproterenol increases the inward sodium current (INa) in rabbit cardiac myocytes23,24 and guinea pig myocytes,26 although this has not been a universal finding in isolated cells. 42, 43 Most pertinent to the current study, Lee et (1) by decreasing the APD,o with subsequent increases in the interpulse interval, allowing a longer time period for Na channel recovery and subsequent facilitation of ventricular conduction; (2) by shortening the plateau, whereby there may be less amiodarone binding to Na channels and less amiodarone-induced reduction in INa45; (3) by causing hyperpolarization of the cell with subsequent reduction in amiodarone-induced Na blockade45; and (4) possibly by facilitating conduction across gap junctions or improving cell-to-cell coupling. 46 
Effects on Repolarization and Refractoriness
This study demonstrates that a dose of isoproterenol that results in physiological changes in heart rate in the drug-free state consistent with moderate physical exercise caused sematilide-induced APD90 prolongation to be fully reversed. Isoproterenol activates a variety of ventricular myocyte currents including the delayed rectifier potassium current (IK), the Na-K pump current, the transient outward potassium current ('to), the chloride current (Ici), and the slow inward calcium current (ICa). ' The somewhat larger reductions in the RVERP in our study along with the mild decrease in the VT cycle length during isoproterenol in patients receiving amiodarone is probably related to the more potent P-adrenergic stimulation in the current investigation. Calkins et a122 used epinephrine, which, on a weight basis, is not as potent a stimulator of cardiac ,l-receptors as is isoproterenol. They only observed a reduction in the sinus cycle length of 4.5% to 7.7% during epinephrine administration in patients receiving amiodarone compared with 28% observed in the current study. In addition, epinephrine stimulates a-receptors, which lengthens the RVERP and may attenuate the effects of ,B-stimulation on refractoriness. 52 
